Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2022-11-09 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2022-11-09 English
6-K
Foreign Filer Report
2022-11-03 English
Earnings Release 2022
Earnings Release Classification · 1% confidence The document is a 'Company Announcement' dated November 3, 2022, titled 'Genmab Improves Its 2022 Financial Guidance'. It explicitly revises previously issued financial guidance for revenue, operating expenses, and operating profit for the year 2022. This type of announcement, which provides key financial updates outside of a full quarterly or annual report, aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial results and key highlights. Although it mentions the upcoming full financial results publication date (November 9, 2022), the content itself is a guidance update, which is a form of earnings-related communication. It is not a full report (10-K or IR), a transcript (CT), or a presentation (IP). Given the focus on updated financial metrics and guidance, ER is the most appropriate classification. FY 2022
2022-11-03 English
Genmab Improves Its 2022 Financial Guidance
Earnings Release Classification · 1% confidence The document is a 'Company Announcement' from Genmab regarding an update to their 2022 financial guidance. It provides specific revised figures for revenue, operating expenses, and operating profit. While it discusses financial performance, it is an initial announcement of updated guidance rather than a full quarterly or annual report. According to the provided definitions, an initial announcement of financial results or guidance highlights is classified as an Earnings Release (ER). FY 2022
2022-11-03 English
6-K
Foreign Filer Report
2022-10-18 English
Earnings Release 2022
Earnings Release Classification · 1% confidence The document is titled "Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022" and provides specific financial figures (USD 2,052 million in net sales) for a defined period (Q3 2022). This structure—announcing key financial results for a specific reporting period (quarterly)—is the defining characteristic of an Earnings Release (ER). It is not a full, comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a general regulatory filing (RNS). It is the initial announcement of results. Q3 2022
2022-10-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.